The National Law Journal and Law360 reported that Ross Feller Casey filed the first three lawsuits in Philadelphia involving serious cardiovascular events suffered by man as a result of taking testosterone-containing drugs.
The separate suits were filed over two weeks on behalf of men from Alabama, New Jersey and Scranton, Pennsylvania who suffered a stroke, a heart attack, and severe heart damage, respectively, while on so-called “Low T” therapy drugs.
Dr. Mark A. Hoffman, an attorney with Ross Feller Casey who is handling the litigation along with founding partners Robert Ross, Joel Feller and Matt Casey, told Law360 that the testosterone lawsuits are believed to be the first of their kind filed in Philadelphia, but certainly not the last.
Ross Feller Casey is reviewing many other reports from men across the nation who suffered serious cardiovascular problems while on testosterone therapy drugs. The firm expects to bring other Low T lawsuits in the coming weeks.
“The train is just leaving the station on these cases, and there’s going to be a lot more to come in terms of there being a flurry of activity,” Hoffman told Law360.
The first two suits were brought against Auxilium Pharmaceuticals, Inc. the makers of Testim, and the drug’s co-promoter, GlaxoSmithKline, LLC. The third suit is against Auxilium, and Abbott Laboratories and AbbVie, the makers of AndroGel.
All three suits, The National Law Journal reported, accuse the manufacturers of failing to test the safety of the drugs as well as concealing the dangers associated with their use.
The lawsuits also allege that the drug makers pushed aggressive advertising campaigns to convince consumers that symptoms associated with the normal male aging process were actually a “syndrome” or a “disease” known as “Low T.”
Hoffman told Law360 that such marketing techniques raise many legal and ethical issues. Testim, he added, is a “drug in search of a reason to give it.”
For more information, go to http://www.rossfellercasey.com/practice-areas/lowtlawsuit/